Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Medtech Tags
  5. Medtech

Medtech

Thumbnail
August 11, 2022

Reva revives

Thumbnail
August 05, 2022

Delfi aims for a cheaper liquid biopsy

With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.

Article image
Vantage logo
August 02, 2022

Perkinelmer sells rather than spins

Article image
Vantage logo
July 29, 2022

Quanterix backs tau for Alzheimer’s diagnosis

Article image
Vantage logo
July 27, 2022

3M to unstick its healthcare unit

Article image
Vantage logo
July 25, 2022

Device approvals drop, but the FDA has a plan

Increased headcount should allow the FDA to up the number of approvals – but not quite yet.

Article image
Vantage logo
July 22, 2022

Venture financing holds steady for device makers

Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.

Article image
Vantage logo
July 20, 2022

The other shoe finally drops for device dealmaking

A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.

Article image
Vantage logo
July 15, 2022

Despair engulfs smaller device companies

The nightmare on the public markets is not confined to the bigger groups.

Article image
Vantage logo
July 14, 2022

Big medtech's share price bloodbath

The worst half-year period for a decade leaves the biggest medical device companies half a trillion dollars poorer.

Article image
Vantage logo
July 11, 2022

Vertex spends $320m on Semma mark 2

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 10, 2022

Q2 Roundup eBook

July 28, 2022

Access Valuable Insights Payer Behaviour Infographic

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.